The report, titled “Anti-Hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline” details different aspects of the market by analyzing it thoroughly. It forecasts the Asia-Pacific antihypertensive therapeutics market to expand at a CAGR of 5.1% to reach a value of US$27 bn by 2022 from $19.1 billion in 2015.
The report begins with a proper description of the malady which includes epidemiology, etiology and pathophysiology, and diagnosis. Hypertension occurs when the arterial blood pressure jumps to 140/90mm Hg or beyond. Elderly people are most prone to this chronic medical condition, which usually does not have any symptoms. Hypertension, however, but can damage different organs on account of the high blood pressure. It can be cured through treatment or by bringing about changes in the lifestyle. Deaths caused by hypertension can be significantly reduced with timely therapeutic intervention.
Some of the primary growth drivers in the Asia Pacific anti-hypertensive therapeutics market are a rising elderly population, higher sodium intake on a daily basis, increasing prevalence of obesity and overweight issues, a shift towards sedentary lifestyle, increasing smoking and alcohol consumption, and a wide array of healthcare reforms. Countering the growth in the market is the weak pipeline of drugs, soaring popularity of generic drugs, non-pharmacological first-line treatment, and reduced awareness about hypertension among physician and common public.
The report offers information on the popular therapies in the anti-hypertensive market and their clinical and commercial standing. Some such treatment options are renin inhibitors, angiotensin receptor blockers, beta blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, and diuretics. They can be used either as monotherapy or as combination therapy.
The report studies the anti-hypertensive pipeline and stratify pipeline therapies by the development stage, molecule type, and molecular target. It finds that the present anti-hypertensive therapeutics pipeline is weak, with 112 molecules in different phases of development. The pipeline is comprised primarily of small molecules. At present, the Asia Pacific anti-hypertensive therapeutics market is dominated by generics and there are a limited number of patented products.
The report further divides the Asia Pacific market for anti-hypertensive therapeutics on the basis of geography into China, India, Japan, Australia, and South Korea. It delves into the market in each of the countries to extract information on their sales and revenues, and growth prospects. It predicts Japan to majorly fillip the market in Asia Pacific on account of expensive therapies.
The report brings to the fore the unmet requirements in the market so that savvy players can take advantage of it. The report also discusses the commercial prospects in the anti-hypertensive deals landscape by studying trends in licensing and co-development deals.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org